<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="15647">Leukotriene B4</z:chebi> (<z:chebi fb="0" ids="15647">LTB4</z:chebi>) is a potent neutrophil activator and chemotaxin that is present in increased concentrations in the colonic tissue and rectal dialysates of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> patients </plain></SENT>
<SENT sid="1" pm="."><plain>Cotton-top tamarins (CTTs) with confirmed active <z:hpo ids='HP_0002583'>colitis</z:hpo> were treated with the second generation <z:chebi fb="0" ids="15647">LTB4</z:chebi> receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, SC-53228 ((+)-(S)-7-[3-(2-<z:chebi fb="0" ids="30364">cyclopropyl</z:chebi>-<z:chebi fb="36" ids="29309">methyl</z:chebi>)-3-<z:chebi fb="8" ids="32772">methoxy</z:chebi>-4-[(<z:chebi fb="0" ids="44209">methylamino</z:chebi>) <z:chebi fb="1" ids="23019">carbonyl</z:chebi>]phenoxy]<z:chebi fb="0" ids="46881">propoxy</z:chebi>]-3,4-dihydro-8-<z:chebi fb="1" ids="26308">propyl</z:chebi>-2H-1-<z:chebi fb="0" ids="22727">benzopyran</z:chebi>-2- <z:chebi fb="0" ids="30768">propanoic acid</z:chebi>), 20 mg/kg bodyweight by gavage, twice daily for 56 days </plain></SENT>
<SENT sid="2" pm="."><plain>End points were body weights, stool consistency, colonic endoscopy, assay of <z:mp ids='MP_0002501'>inflammatory mediators</z:mp>, and haematology and clinical chemistry tests </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="15647">LTB4</z:chebi> and <z:chebi fb="11" ids="26333">prostaglandin</z:chebi> E (<z:chebi fb="0" ids="26338">PGE</z:chebi>) values were measured in rectal dialysates at pretreatment, 28 day and 56 day time points </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="15647">LTB4</z:chebi> concentrations were reduced from pretreatment mean (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e>) values of 37.3 (0.8) ng/ml to 3.7 (0.8) ng/ml (p &lt; 0.001) and 2.3 (0.5) ng/ml (p &lt; 0.01) at days 28 and 56, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>On the other hand, mucosal protective <z:chebi fb="0" ids="26338">PGE</z:chebi> values remained constant or slightly increased during SC-53228 treatment (pre: 6.9 (2.2) ng/ml; day 28: 6.7 (1.4) ng/ml; day 56: 9.9 (1.6) ng/ml) </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore, assessment of a panel of 35 clinical chemistry and haematology parameters throughout the treatment showed there were no significant untoward effects of drug treatment </plain></SENT>
<SENT sid="7" pm="."><plain>Six CCTs finished the eight week treatment and five of six gained weight (ranging from 27-121 grams each) while one CTT lost weight (50 g) </plain></SENT>
<SENT sid="8" pm="."><plain>Stool condition improved in five of six animals while one of six remained unchanged </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> CCTs showed dramatic improvement histologically, with no or only minimally active <z:hpo ids='HP_0002583'>colitis</z:hpo> after treatment </plain></SENT>
<SENT sid="10" pm="."><plain>The histological changes plus significant <z:mp ids='MP_0005456'>weight gains</z:mp> and improvement of stool condition (quality of life parameters) after eight weeks of SC-53228 treatment were remarkable </plain></SENT>
<SENT sid="11" pm="."><plain>Furthermore, in follow up biopsies seven months after treatment ceased, three of six CTTs had no active <z:hpo ids='HP_0002583'>colitis</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>This is the first time afflicted CTTs have not had recurring colitic exacerbations after a treatment regimen was stopped </plain></SENT>
<SENT sid="13" pm="."><plain>It is concluded that in colitic CTTs, SC-53228 has shown both an immediate and a long acting anticolitic activity </plain></SENT>
<SENT sid="14" pm="."><plain>It is also concluded that reduced <z:chebi fb="0" ids="15647">LTB4</z:chebi> concentrations during treatment inhibited neutrophil infiltration of the colonic tissue and this, coupled with the maintenance of mucosal protective <z:chebi fb="11" ids="26333">prostaglandins</z:chebi>, contributed to the dramatic anticolitic efficacy </plain></SENT>
<SENT sid="15" pm="."><plain>The treatment was safe over eight weeks </plain></SENT>
<SENT sid="16" pm="."><plain>A compound such as SC-53228 may be useful in the medical treatment of human <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> </plain></SENT>
</text></document>